Compare Gilead Sciences, Inc. (GILD) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Matson Inc — how do they compare? Gilead Sciences, Inc. trades at $136.43 (market cap $168.35B), while Matson Inc trades at $212.56 (market cap $6.11B). The key difference: Gilead Sciences, Inc. is far larger — about 27.6× Matson Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | MATX | |
|---|---|---|
Market Cap | $168.35B | $6.11B |
Sector | Health | Technology |
52-Week High | $155.80 | $223.55 |
52-Week Low | $110.56 | $88.05 |
Enterprise Value | $191.42B | $6.71B |
Dividend Yield | 2.42% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Matson (MATX) trades at $212.05, up 1.61% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.27 surpassing expectations. Revenue and net income are trending upward, supported by a robust China service and resilient consumer demand. The company's valuation ratios, including a P/E of 13.79 and EV/EBITDA of 7.78, appear reasonable relative to earnings growth.
The outlook for MATX is positive, driven by earnings momentum and a favorable analyst consensus with a $265 price target implying significant upside. Key opportunities include continued trade flow strength and dividend growth, while risks involve Trans-Pacific trade volatility and broader economic pressures. The stock presents a compelling case for growth-oriented investors seeking exposure to niche shipping services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
